GLP-1受体激动剂与2型糖尿病合并慢性下呼吸道疾病急性加重的关系
本研究基于2005-2017年美国商业保险索赔数据库,纳入合并2型糖尿病和慢性下呼吸道疾病(CLRD)的成人,比较启动GLP-1受体激动剂(GLP-1RA)与二肽基肽酶4抑制剂(DPP-4I)作为附加治疗者的CLRD急性加重风险。结果显示GLP-1RA组首次CLRD住院调整后风险比显著低于DPP-4I组,任何CLRD急性加重调整后发生率比亦较低。
要点
- 合并T2D与CLRD患者中,GLP-1RA较DPP-4I与更低的CLRD急性加重风险相关。
- GLP-1RA组首次CLRD住院调整后HR为0.52(95%CI 0.32-0.85)。
- 任何CLRD急性加重调整后IRR为0.70(95%CI 0.57-0.87)。
核心结论
- 与DPP-4I相比,GLP-1RA使用者CLRD急性加重次数更少。
- 基于机制通路和真实世界证据,选择降糖方案时可考虑GLP-1RA的潜在获益。
- 需随机临床试验证实上述发现。
研究设计与样本
- 新使用者主动对照分析,使用2005-2017年美国全国商业保险索赔数据库。
- 纳入合并T2D和CLRD、在降糖方案中附加GLP-1RA或DPP-4I的成人。
- 样本包括4,150例GLP-1RA新使用者和12,540例DPP-4I新使用者。
主要发现
- 随访期间首次CLRD住院调整后发生率:GLP-1RA组10.7/1000人年,DPP-4I组20.3/1000人年。
- 首次CLRD住院调整后风险比为0.52(95%CI 0.32-0.85)。
- 任何CLRD急性加重(住院或门诊就诊)调整后发生率比为0.70(95%CI 0.57-0.87)。
临床怎么用
- 合并T2D和CLRD的患者选择降糖药物时,可考虑GLP-1RA的潜在呼吸获益。
- 该证据来自真实世界观察性研究,需结合患者个体情况并等待随机试验确认。
局限性
- 为观察性研究,可能存在残余混杂。
- 结论需随机临床试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Emerging data from animal and human pilot studies suggest potential benefits of glucagon-like peptide 1 receptor agonists (GLP-1RA) on lung function. We aimed to assess the association of GLP-1RA and chronic lower respiratory disease (CLRD) exacerbation in a population with comorbid type 2 diabetes (T2D) and CLRD. RESEARCH DESIGN AND METHODS: A new-user active-comparator analysis was conducted with use of a national claims database of beneficiaries with employer-sponsored health insurance spanning 2005-2017. We included adults with T2D and CLRD who initiated GLP-1RA or dipeptidyl peptidase 4 inhibitors (DPP-4I) as an add-on therapy to their antidiabetes regimen. The primary outcome was time to first hospital admission for CLRD. The secondary outcome was a count of any CLRD exacerbation associated with an inpatient or outpatient visit. We estimated incidence rates using inverse probability of treatment weighting for each study group and compared via risk ratios. RESULTS: The study sample consisted of 4,150 GLP-1RA and 12,540 DPP-4I new users with comorbid T2D and CLRD. The adjusted incidence rate of first CLRD admission during follow-up was 10.7 and 20.3 per 1,000 person-years for GLP-1RA and DPP-4I users, respectively, resulting in an adjusted hazard ratio of 0.52 (95% CI 0.32-0.85). For the secondary outcome, the adjusted incidence rate ratio was 0.70 (95% CI 0.57-0.87). CONCLUSIONS: GLP-1RA users had fewer CLRD exacerbations in comparison with DPP-4I users. Considering both plausible mechanistic pathways and this real-world evidence, potential beneficial effects of GLP-1RA may be considered in selection of an antidiabetes treatment regimen. Randomized clinical trials are warranted to confirm our findings.
引用
- Albogami Y, Cusi K, Daniels MJ, et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care. 2021. PMID: 33875487. doi:10.2337/dc20-1794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。